Navarro v. Walgreens Boots Alliance, Inc.

Summary

The document contains findings and recommendations recommending that the Eastern District of California grant Walgreens Boots Alliance, Inc.’s motion to dismiss a putative consumer class action concerning benzoyl peroxide acne products allegedly containing or degrading into benzene. The court addresses standing, failure to state a claim, federal preemption, primary jurisdiction, pleading requirements, statutory bars, and equitable and injunctive relief. Objections to the recommendations are due within fourteen days.

Holdings

1. Plaintiffs sufficiently alleged economic injury and therefore adequately pleaded injury in fact for Article III standing at the motion-to-dismiss stage.
2. Claims based on the allegation that Walgreens should have added a benzene warning to the labels of its over-the-counter acne products are expressly preempted.
3. Claims premised on Walgreens's failure to list benzene as an inactive ingredient are preempted because benzene was alleged to be an unintended degradation product, not a component intended for use in manufacturing.
4. State-law claims based on alleged violations of current good manufacturing practices are not categorically preempted to the extent they impose requirements parallel to federal requirements rather than directly enforce the FDCA.
5. Plaintiffs failed to plead the how of their alleged deception with the particularity required by Rule 9(b), because they did not allege facts establishing a cGMP violation or explaining how any such violation deceived them.
6. Plaintiffs should be granted leave to amend because the deficiencies identified might be cured by additional factual allegations and no basis for denying amendment was shown.

Questions Presented

1. Whether Plaintiffs adequately alleged an injury in fact sufficient to establish Article III standing.
2. Whether federal law expressly preempts claims based on Walgreens's failure to warn on product labels that the products contained or could degrade into benzene.
3. Whether federal law preempts claims based on treating benzene as an inactive ingredient that was required to be listed on the products' labels.
4. Whether state-law claims based on alleged violations of current good manufacturing practices may proceed as parallel claims.
5. Whether Plaintiffs pleaded their fraud-based claims with the particularity required by Federal Rule of Civil Procedure 9(b).
6. Whether the action should be dismissed or stayed under the primary-jurisdiction doctrine.
7. Whether Plaintiffs should receive leave to amend.

Disposition

other